Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BCRX 
BioCryst Pharmaceuticals Inc (BCRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/23/2025: BCRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $20.27
1 Year Target Price $20.27
| 6 | Strong Buy |
| 5 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -22.12% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/23/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.51B USD | Price to earnings Ratio - | 1Y Target Price 20.27 |
Price to earnings Ratio - | 1Y Target Price 20.27 | ||
Volume (30-day avg) 12 | Beta 1.04 | 52 Weeks Range 6.00 - 11.31 | Updated Date 10/24/2025 |
52 Weeks Range 6.00 - 11.31 | Updated Date 10/24/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.18 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -6.41% | Operating Margin (TTM) 18.23% |
Management Effectiveness
Return on Assets (TTM) 7.46% | Return on Equity (TTM) -1925.37% |
Valuation
Trailing PE - | Forward PE 20.37 | Enterprise Value 1981854751 | Price to Sales(TTM) 2.72 |
Enterprise Value 1981854751 | Price to Sales(TTM) 2.72 | ||
Enterprise Value to Revenue 3.55 | Enterprise Value to EBITDA 31.24 | Shares Outstanding 210529583 | Shares Floating 195517789 |
Shares Outstanding 210529583 | Shares Floating 195517789 | ||
Percent Insiders 1.19 | Percent Institutions 98.87 |
Upturn AI SWOT
BioCryst Pharmaceuticals Inc
Company Overview
History and Background
BioCryst Pharmaceuticals, Inc. was founded in 1986. It is focused on discovering, developing, and commercializing novel small-molecule medicines that address unmet medical needs. Over time, BioCryst transitioned from focusing on structural biology to drug discovery and development, with key milestones including the approval of its first drug, Peramivir, and the later development of Orladeyo.
Core Business Areas
- Rare Disease Therapeutics: Focuses on the development and commercialization of treatments for rare diseases, specifically hereditary angioedema (HAE) and paroxysmal nocturnal hemoglobinuria (PNH).
- Discovery and Development: Continues to engage in research and development activities to discover and develop new small-molecule drugs targeting various therapeutic areas.
Leadership and Structure
The leadership team is headed by Jon P. Stonehouse, the CEO. The organizational structure includes departments focused on research and development, commercial operations, finance, and legal affairs. The Board of Directors provides oversight and strategic guidance.
Top Products and Market Share
Key Offerings
- Orladeyo (berotralstat): Orladeyo is an oral, once-daily medicine for the prevention of hereditary angioedema (HAE) attacks in adult and pediatric patients 12 years and older. It has gained significant market share in the HAE prophylaxis market and is a major revenue driver for BioCryst. Competitors include Takhzyro (lanadelumab) from Takeda and Haegarda (C1 esterase inhibitor [human]) from CSL Behring. Total Orladeyo net revenue for 2023 was $324.1 million.
- Rapivab (peramivir): Rapivab is an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza. It is primarily used in hospital settings. While still contributing to revenue, Rapivab is not a primary growth driver compared to Orladeyo. Competitors include Tamiflu (oseltamivir) and Xofluza (baloxavir marboxil).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by intense competition, high R&D costs, and a complex regulatory landscape. The market for rare disease therapeutics is growing, driven by increased awareness, improved diagnostics, and regulatory incentives for orphan drug development.
Positioning
BioCryst is positioned as a leader in the HAE prophylaxis market with Orladeyo. Its competitive advantage lies in the oral administration and favorable safety profile of Orladeyo, offering a convenient alternative to injectable treatments. BioCryst is also positioning itself in the PNH market with BCX9930, targeting a significant market with high unmet need.
Total Addressable Market (TAM)
The HAE market is estimated to be billions of dollars. The PNH market is also substantial. BioCryst is positioned to capture a significant portion of these markets with Orladeyo and potential future therapies.
Upturn SWOT Analysis
Strengths
- Strong presence in the HAE prophylaxis market with Orladeyo
- Oral administration provides a convenient alternative to injectable therapies
- Growing revenue and profitability
- Robust pipeline of potential new therapies
Weaknesses
- Reliance on Orladeyo for revenue
- BCX9930 has faced regulatory hurdles
- Competition from established pharmaceutical companies
- High R&D costs and regulatory risks
Opportunities
- Expansion of Orladeyo into new markets and indications
- Development and commercialization of BCX9930 for PNH and other complement-mediated diseases
- Strategic partnerships and acquisitions to expand pipeline
- Potential for pipeline assets to address significant unmet needs
Threats
- Competition from existing and emerging HAE therapies
- Regulatory delays or rejection of new drug applications
- Patent expiration and generic competition
- Adverse events or safety concerns with existing or pipeline therapies
Competitors and Market Share
Key Competitors
- TAK
- CSL
Competitive Landscape
BioCryst's oral therapy Orladeyo provides a competitive advantage versus injectable therapies. However, Takeda and CSL Behring are well-established players in the rare disease market with strong pipelines and commercial capabilities.
Growth Trajectory and Initiatives
Historical Growth: BioCryst has experienced rapid revenue growth in recent years due to the commercial success of Orladeyo.
Future Projections: Analysts project continued revenue growth for BioCryst, driven by increasing Orladeyo sales and potential approval of pipeline therapies.
Recent Initiatives: Recent strategic initiatives include expanding the commercial reach of Orladeyo, advancing the clinical development of BCX9930, and exploring new therapeutic targets.
Summary
BioCryst shows strength with Orladeyo's market presence and high gross margins. Challenges remain in achieving consistent net profitability and BCX9930's regulatory path. The company needs to manage competition and R&D risks carefully while capitalizing on market opportunities.
Peer Comparison
Sources and Disclaimers
Data Sources:
- BioCryst Pharmaceuticals Inc. Investor Relations
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BioCryst Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Durham, NC, United States | ||
IPO Launch date 1994-03-03 | CEO & Executive Director Mr. Jon P. Stonehouse | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 580 | Website https://www.biocryst.com |
Full time employees 580 | Website https://www.biocryst.com | ||
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in preclinical phase; and BCX10013, an oral Factor D inhibitor for complement-mediated diseases, as well as developing Oral C5 Inhibitor and Oral C2 Inhibitor. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Shionogi & Co., Ltd., Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.